Health Affairs, 24, no. 3 (2005): 666-679
doi: 10.1377/hlthaff.24.3.666
© 2005 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Web of Science (8)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Lieu, T. A.
* Articles by Hinman, A. R.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Lieu, T. A.
* Articles by Hinman, A. R.
Related Collections
* Health Promotion/Disease Prevention
* International Issues
* Public Health
* Research And Technology
* Consumer Issues
* Vaccines

Financing

Overcoming Economic Barriers To The Optimal Use Of Vaccines

Tracy A. Lieu, Thomas G. McGuire and Alan R. Hinman

Vaccines are among the most cost-effective interventions in health care, but economic factors may interfere with their optimal development and delivery in both industrialized and developing countries. For the United States, making the best use of available vaccines will require increasing the financing for vaccines via the public and private systems. For developing countries, innovative and promising approaches include pull mechanisms to establish predictable demand and push mechanisms such as targeted development programs. Partnerships between philanthropy and public resources have made progress in addressing gaps in vaccine financing and development for developing countries, but much remains to be done.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
PediatricsHome page
L. A. Prosser, C. Y. Kong, D. Rusinak, and S. L. Waisbren
Projected Costs, Risks, and Benefits of Expanded Newborn Screening for MCADD
Pediatrics, February 1, 2010; 125(2): e286 - e294.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
M. A. O'Brien, L. A. Prosser, J. L. Paradise, G. T. Ray, M. Kulldorff, M. Kurs-Lasky, V. L. Hinrichsen, J. Mehta, D. K. Colborn, and T. A. Lieu
New Vaccines Against Otitis Media: Projected Benefits and Cost-effectiveness
Pediatrics, June 1, 2009; 123(6): 1452 - 1463.
[Abstract] [Full Text] [PDF]


Home page
Public Health EthicsHome page
S. W. Jarrett
Challenges to the Successful Introduction of Biotechnologies in Developing Countries
Public Health Ethics, July 1, 2008; 1(2): 104 - 109.
[Full Text] [PDF]


Home page
JAMAHome page
S. W. Roush, T. V. Murphy, and and the Vaccine-Preventable Disease Table Working
Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States
JAMA, November 14, 2007; 298(18): 2155 - 2163.
[Abstract] [Full Text] [PDF]


Home page
Policy Politics Nursing PracticeHome page
E. G. Cohn
Including Marginalized Populations in HIV Clinical Trials: A New Role for Nurse-Researchers
Policy Politics Nursing Practice, November 1, 2007; 8(4): 271 - 275.
[Abstract] [PDF]


Home page
JAMAHome page
M. M. Mello and T. A. Brennan
Legal Concerns and the Influenza Vaccine Shortage
JAMA, October 12, 2005; 294(14): 1817 - 1820.
[Full Text] [PDF]